Here are relevant reports on : autoimmune-disease-diagnostics-market
-
Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029
The global immunotherapy drugs market, valued at US$255.9 billion in 2023, stood at US$285.3 billion in 2024 and is projected to advance at a resilient CAGR of 15.3% from 2024 to 2029, culminating in a forecasted valuation of US$580.6 billion by the end of the period. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Stem Cell Banking Market by Source (PSC, BMSC, ADSC, hESC, DPSC, NSC), Service Type (Sample Processing, Analysis, Collection, Storage), Application (Personalized Storage, Clinical (Autoimmune, Hematopoietic Disorders), Research) - Global Forecasts to 2023
The global stem cell banking market is projected to reach USD 9.30 Billion by 2023, at a CAGR of 8.2%. Major players in the global stem cell banking market include Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico).
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
The global monoclonal antibody therapeutics market, valued at US$222.6 billion in 2023, stood at US$252.6 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$497.5 billion by the end of the period. Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Esoteric Testing Market by Type (Endocrinology, Oncology, Neurology, Genetic Tests, Autoimmune, Infectious Diseases), Technology (ELISA, CLIA, Flow Cytometry, NGS, RT-PCR, Chromatography, Spectrometry), Specimen (Blood, Urine) - Global Forecast to 2029
The global esoteric testing market, valued at US$29.9 billion in 2023, stood at US$32.2 billion in 2024 and is projected to advance at a resilient CAGR of 8.5% from 2024 to 2029, culminating in a forecasted valuation of US$48.3 billion by the end of the period. Growth in the market is primarily driven by the growing geriatric population, advancements in esoteric tests for personalized medicine, increasing research funding for precision medicine, and increase in drug and alcohol abuse and stringent laws mandating drug and alcohol testing.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024
The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035
The global biosimilars market is projected to reach USD 72.29 billion by 2035, growing at a CAGR of 7.5% during the forecast period (2025–2035). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Respiratory Care Devices Market by Product (PAP Devices, Ventilators, Humidifiers, Oxygen Concentrators, Spirometers, Peak Flow Meter, Masks), Disease Indication (Asthma, Infectious Disease), End User (Hospitals, Homecare Settings) - Global Forecast to 2030
The global respiratory care devices market, valued at US$22.2 billion in 2024, stood at US$23.6 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of US$33.6 billion by the end of the period. Various demographic, medical, and environmental factors propel market growth in respiratory care equipment. Among these is the increase in the global prevalence of respiratory conditions.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Periodontal Disease Treatment Market by Product (Equipment, Consumables), Disease (Gingivitis, Periodontitis), Treatment (Bone Grafting, Scaling, Flap Surgery, Regeneration), End User (Clinics, Private DSOs), and Country - Forecast to 2031
The Asia Pacific peritoneal dialysis market, valued at USD 0.60 billion in 2025, stood at USD 0.64 billion in 2026 and is projected to advance at a resilient CAGR of 6.0% from 2026 to 2031, culminating in a forecasted valuation of USD 0.91 billion by the end of the period. The Asia Pacific periodontal disease treatment market is driven by the increasing prevalence of oral health disorders and the rising cases of edentulism, which are creating a growing need for effective periodontal care.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Respiratory Care Device Market by Product (PAP Devices, Ventilators, Humidifiers, Oxygen Concentrators, Spirometers, Peak Flow Meter, Masks), Disease Indication (Asthma, Infectious Disease), & End User (Hospitals, ASCs) - Forecast to 2031
The Asia Pacific respiratory care devices market is projected to reach USD 8.76 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Europe Respiratory Care Device Market Product (PAP Devices, Ventilators, Humidifiers, Oxygen Concentrators, Spirometers, Peak Flow Meter, Masks), Disease Indication (Asthma, Infectious Disease), End User (Hospitals, Homecare Settings)- Regional Forecast to 2031
The europe respiratory care devices market, valued at USD 5.97 billion in 2025, stood at USD 6.33 billion in 2026 and is projected to advance at a resilient CAGR of 7.2% from 2026 to 2031, culminating in a forecasted valuation of USD 8.96 billion by the end of the period. The key players in the Europe respiratory care devices market are Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), ResMed Inc. (US), Fisher & Paykel Healthcare Limited (New Zealand), Drägerwerk AG & Co. KGaA (Germany), GE Healthcare (US), Masimo (US), and among other players.
- Published: August 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
